iUni G2+ Prospective Study
Study Details
Study Description
Brief Summary
This study is designed to monitor long term clinical outcomes of the iUni G2+ unicompartmental knee replacement
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The study subjects will be followed for 10 years post implant. The follow-up visit schedule will include visits at 6 weeks, 6 months, 1 year, 2 years, 5 years and 10 years post implant.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| iUni G2+ iUni G2+ in all patients |
Device: iUni G2+
The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
|
Outcome Measures
Primary Outcome Measures
- 2011 Knee Society Score [1 Year]
- KOOS Score [1 Year]
- Oxford Knee Score [1 Year]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Clinical condition included in the approved Indications For Use
-
Unicompartmental osteoarthritis of the medial or lateral tibiofemoral compartment
-
Willingness to participate in the clinical study, to give informed consent, and to attend all follow-up visits
-
18 years of age
Exclusion Criteria:
-
Simultaneous bilateral procedure required
-
BMI > 35
-
Treatment for cancer within the past 5 years, with the exception of skin cancer
-
Poorly controlled diabetes
-
Neuromuscular conditions which prevent patient from participating in study activities
-
Active local or systemic infection
-
Immunocompromised
-
Fibromyalgia or other general body pain related condition
-
Advanced tricompartmental osteoarthritis
-
Symptomatic patellofemoral disease
-
Rheumatoid arthritis or other forms of inflammatory joint disease (excluding Gout unless it is in the treated knee or limiting overall function)
-
Loss of bone or musculature, osteoporosis, osteonecrosis, neuromuscular or vascular compromise in the area of the joint to be operated to an extent that the procedure is unjustified. Osteoporosis is defined by more than -2.5 standard deviations from the T score as measured on a Dual Energy X-Ray Absortiometry Scan (DEXA) within 2 years of surgery.
-
Advanced loss of osteochondral structure on the affected femoral condyle
-
Compromised ACL, PCL or collateral ligament
-
Severe (>15º) fixed valgus or varus deformity
-
Extension deficit > 15 º
-
Prior history of failed implant surgery of the joint to be treated
-
Unwilling or unable to comply with study requirements
-
Participation in another clinical study which would confound results
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The London Clinic | London | United Kingdom |
Sponsors and Collaborators
- ConforMIS, Inc.
Investigators
- Principal Investigator: Dinesh Nathwani, MD, The London Clinic
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 12-004